ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire To Get Movetis

by Lisa M. Jarvis
August 9, 2010 | APPEARED IN VOLUME 88, ISSUE 32

Shire has agreed to pay $430 million for Movetis, a Belgium-based specialty pharmaceuticals firm focused on gastrointestinal products. Shire says Movetis, spun off from Johnson & Johnson in 2006, complements its existing GI portfolio while also expanding its presence outside the U.S. The deal includes Resolor, a chronic-constipation treatment, and a pipeline of GI drug candidates that includes two compounds in Phase II clinical trials and two in preclinical development. Shire expects Resolor’s peak sales to top $400 million per year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment